Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: Implications for Parkinson’s disease

Abstract

Alpha-synuclein has been reported to be present in the nucleus and levels enhanced by oxidative stress. Herein, we sought to investigate the mechanistic role of nuclear alpha-synuclein. We found that alpha-synuclein nuclear localization coincided with enhanced chromatin binding both in an in vitro and a corresponding in vivo brain oxidative stress model previously characterized by our laboratory as well as in PD brain tissues. Genome-wide chromatin immunoprecipitation (ChIP)-on-chip analysis of alpha-synuclein:promoter binding in response to oxidative stress in vitro revealed that binding occurs at several promoters belonging to a range of functional categories including transcriptional regulation. Interestingly, given the important role of mitochondrial dysfunction in PD, this included binding to the promoter for the master mitochondrial transcription activator, PGC1alpha in vitro, in vivo, and in human brain tissue with age and PD. To test the possible mechanistic impact of alpha-synuclein PGC1alpha promotor binding, we assessed PGC1alpha promoter activity, mRNA, and protein levels and expression of candidate PGC1alpha-target genes in our in vitro model. All were found to be reduced in conjunction with increased levels of aberrant mitochondrial morphology and impaired mitochondrial function. Exogenous PGC1alpha expression was found to attenuate alpha-synuclein-mediated mitochondrial dysfunction and subsequent neurotoxicity in vitro. Our data suggests that nuclear alpha-synuclein localization under conditions of oxidative stress may impact on mitochondrial function in part via the protein’s capacity to act as a transcriptional modulator of PGC1alpha. This represents a novel role for alpha-synuclein as it relates to mitochondrial dysfunction in PD.

Sirtuins and their interactions with transcription factors and poly(ADP-ribose) polymerases

“…PPARγ co-activator 1α (PGC-1α) is an important player in the PPAR network, capable of modulating respiration/oxidative stress resistance [183] and neuronal survival. Its ASN-induced [221] disturbances may be implicated in the pathogenesis of Parkinson's disease [40], and PGC-1α has been proposed as a therapeutic target in PD [239].…”

α-Synuclein and Mitochondria: Partners in Crime?

“…Lastly, synuclein may also affect more general aspects of mitochondrial function. For instance, under conditions of oxidative stress, an increased fraction of synuclein localizes to the nucleus and binds to the PGC1α promoter, and a consequent down-regulation in PGC1α-target genes could contribute indirectly to changes in mitochondrial morphology and/or function [34].…”

Microdeletions involving Chromosomes 12 and 22 Associated with Syndromic Duane Retraction Syndrome

“…It is a major factor regulating muscle fibre determination and has been recently implicated as a potential therapy target for Parkinson's disease. 43 Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear receptor proteins that function as transcription factors. 44 PPARs form heterodimers with the retinoid X-receptor and regulate expression of genes involved in cell proliferation, differentiation, metabolism, and inflammation processes, 45 including having a role in promoting cranial neural crest cell survival.…”